Markets:

Overview

News

Currencies

International

Treasuries

Csl Ltd ADR (OP:CSLLY)

23.98 -0.13 (-0.54%)

Streaming Delayed Price Updated: 1:21 PM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Csl Ltd ADR

< Previous 1 2 Next >

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗

June 20, 2025

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

Via Investor's Business Daily

European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

February 14, 2025

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Life Sciences Investor Forum: Now Available for Online Viewing

June 13, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗

February 07, 2025

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

Via Benzinga

CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

December 09, 2024

From ON24

Via Business Wire

Life Sciences Investor Forum Agenda Announced for June 11th-12th

June 10, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

October 17, 2024

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial

From Travere Therapeutics, Inc.

Via GlobeNewswire

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses ↗

September 30, 2024

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...

Via Benzinga

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

September 30, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

CSL Joins Accumulus Synergy to Drive Industry Change

September 17, 2024

Following the launch of Accumulus Synergy’s innovative cloud-based information exchange platform, CSL joins the nonprofit industry association

From Accumulus Synergy

Via GlobeNewswire

Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

September 13, 2024

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

July 04, 2024

From CSL Behring

Via GlobeNewswire

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

May 20, 2024

From Arcturus Therapeutics

Via Business Wire

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

April 30, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia ↗

April 26, 2024

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

Via Benzinga

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

April 24, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

April 03, 2024

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia

Via MarketBeat

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

February 23, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 05, 2024

From Arcturus Therapeutics

Via Business Wire

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 21, 2023

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗

December 13, 2023

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Via Benzinga

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 28, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

May 18, 2023

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in...

From Cara Therapeutics, Inc.

Via GlobeNewswire

OTC Markets Group Welcomes CSL Limited to OTCQX

April 27, 2023

From OTC Markets

Via GlobeNewswire

5 Diverse Medical Stocks To Buy For 2023 And Beyond ↗

April 08, 2023

Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and...

Via Talk Markets

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.